Technical Analysis for XRTX - Xortx Therapeutics Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | 4.84% | |
| Wide Bands | Range Expansion | 4.84% | |
| Gapped Down | Weakness | 4.84% | |
| Oversold Stochastic | Weakness | 4.84% | |
| Jack-in-the-Box Bearish | Bearish Swing Setup | -7.14% | |
| Stochastic Buy Signal | Bullish | -7.14% | |
| Narrow Range Bar | Range Contraction | -7.14% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Up 3% | about 9 hours ago |
| Up 2% | about 9 hours ago |
| Up 1% | about 9 hours ago |
| Possible NR7 | about 10 hours ago |
| Bearish 180 Entry | about 12 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 2023-04-11
Xortx Therapeutics Inc Description
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Vancouver, Canada.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medical Specialties Organ Systems Diabetes Infection Hypertension Kidney Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.0 |
| 52 Week Low | 0.6 |
| Average Volume | 21,965 |
| 200-Day Moving Average | 1.359 |
| 50-Day Moving Average | 0.832 |
| 20-Day Moving Average | 0.732 |
| 10-Day Moving Average | 0.671 |
| Average True Range | 0.062 |
| RSI | 40.48 |
| ADX | 11.19 |
| +DI | 17.820 |
| -DI | 26.430 |
| Chandelier Exit (Long, 3 ATRs) | 0.713 |
| Chandelier Exit (Short, 3 ATRs) | 0.787 |
| Upper Bollinger Bands | 0.878 |
| Lower Bollinger Band | 0.586 |
| Percent B (%b) | 0.22 |
| BandWidth | 39.918 |
| MACD Line | -0.055 |
| MACD Signal Line | -0.052 |
| MACD Histogram | -0.0031 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.725 | ||||
| Resistance 3 (R3) | 0.717 | 0.683 | 0.713 | ||
| Resistance 2 (R2) | 0.683 | 0.664 | 0.688 | 0.708 | |
| Resistance 1 (R1) | 0.667 | 0.652 | 0.675 | 0.675 | 0.704 |
| Pivot Point | 0.633 | 0.633 | 0.638 | 0.638 | 0.633 |
| Support 1 (S1) | 0.617 | 0.614 | 0.625 | 0.625 | 0.596 |
| Support 2 (S2) | 0.583 | 0.602 | 0.588 | 0.592 | |
| Support 3 (S3) | 0.567 | 0.583 | 0.588 | ||
| Support 4 (S4) | 0.575 |
